GoldenGolden
Advanced Search
Dynavax Technologies

Dynavax Technologies

A biopharmaceutical company that researches and develops products to prevent infectious disease and treat autoimmune and inflammatory diseases. It was founded in 1996 and is located in Berkeley, California.

Dynavax Technologies is a California-based company in the biotechnology industry with a focus on developing novel vaccines. Its first commercial product was a Hepatitis B vaccine called HEPLISAV-B.It develops its medical solutions using Toll-like Receptor (TLR) technology.

COVID-19

The company entered into a partnership with Clover Biopharmaceuticals, a Chinese biotechnology company, to develop a vaccine candidate for COVID-19. The company's roll in the partnership includes technical expertise as well as CpG 1018, an adjuvant that is used in creating vaccines such as the company's own HEPLISAV-B.

Dynavax Technologies also partnered with Sinovac to combine its adjuvant CpG 1018 with Sinovac's chemically inactivated vaccine candidate for COVID-19.

Timeline

May 27, 2021
Dynavax Technologies Corporation enters into a commercialization agreement with Bavarian Nordic.

Funding rounds

Products

Acquisitions

SBA Awards

Patents

Products

People

Name
Role
LinkedIn

Albert Robinson

Employee

Anton Stetsenko

Employee

Astrid Liong

Employee

Augie Kuo

Investor

David Novack

President and COO

Further reading

Title
Author
Link
Type
Date

Covid 19 vaccine to be worked on by Dynavax, UQ and CEPI.

Web

March 3, 2020

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Dynavax Technologies Corporation

Web

March 24, 2020

Documentaries, videos and podcasts

Title
Date
Link

The Next Big Thing In Biotech: Dynavax

November 9, 2012

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 27, 2021
BioSpace
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany
Clover Biopharmaceuticals
February 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.